Unlocking an expansive target space to build a pipeline of novel, TCR-based therapeutics.

Our Science

At T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in identification of therapeutically relevant targets and TCRs has limited the application of such therapies.
T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.

Media

February 25, 2021

Biocentury

February 25, 2021

BioWorld

February 25, 2021

GlobalNewswire

Get in contact

Schrödinger Building,
Heatley Rd,
Oxford OX4 4GE